HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,877,314 | +6.9% | 1,698,359 | +0.9% | 0.02% | +11.8% |
| Q2 2023 | $60,686,224 | -5.7% | 1,682,457 | -0.2% | 0.02% | -15.0% |
| Q1 2023 | $64,387,385 | -29.8% | 1,685,975 | +4.5% | 0.02% | -33.3% |
| Q4 2022 | $91,780,041 | +44.1% | 1,613,006 | +0.2% | 0.03% | +30.4% |
| Q3 2022 | $63,682,000 | +15.1% | 1,610,579 | +28.0% | 0.02% | +21.1% |
| Q2 2022 | $55,349,000 | +4.7% | 1,257,917 | -5.1% | 0.02% | +18.8% |
| Q1 2022 | $52,849,000 | +1.5% | 1,325,197 | +2.4% | 0.02% | +6.7% |
| Q4 2021 | $52,057,000 | -2.6% | 1,294,615 | -1.5% | 0.02% | -11.8% |
| Q3 2021 | $53,473,000 | -4.2% | 1,314,466 | +6.9% | 0.02% | -10.5% |
| Q2 2021 | $55,820,000 | +17.0% | 1,229,243 | +7.4% | 0.02% | +11.8% |
| Q1 2021 | $47,705,000 | +18.1% | 1,144,269 | +20.9% | 0.02% | +6.2% |
| Q4 2020 | $40,409,000 | +62.5% | 946,113 | -0.0% | 0.02% | +45.5% |
| Q3 2020 | $24,870,000 | +3.6% | 946,317 | +5.7% | 0.01% | -8.3% |
| Q2 2020 | $24,000,000 | +57.2% | 895,161 | +5.5% | 0.01% | +33.3% |
| Q1 2020 | $15,267,000 | -2.9% | 848,614 | -4.3% | 0.01% | +12.5% |
| Q4 2019 | $15,716,000 | +12.0% | 886,362 | -2.1% | 0.01% | 0.0% |
| Q3 2019 | $14,036,000 | -7.7% | 904,946 | +2.2% | 0.01% | -11.1% |
| Q2 2019 | $15,211,000 | +12.3% | 885,353 | +5.2% | 0.01% | 0.0% |
| Q1 2019 | $13,545,000 | +33.2% | 841,281 | +21.0% | 0.01% | +12.5% |
| Q4 2018 | $10,170,000 | -40.5% | 695,083 | -26.1% | 0.01% | -27.3% |
| Q3 2018 | $17,086,000 | +1.4% | 940,292 | -5.9% | 0.01% | -8.3% |
| Q2 2018 | $16,858,000 | -7.2% | 999,260 | +7.8% | 0.01% | -14.3% |
| Q1 2018 | $18,158,000 | +35.6% | 926,868 | +40.2% | 0.01% | +27.3% |
| Q4 2017 | $13,393,000 | +35.1% | 661,013 | +15.9% | 0.01% | +22.2% |
| Q3 2017 | $9,910,000 | +51.0% | 570,513 | +11.5% | 0.01% | +50.0% |
| Q2 2017 | $6,562,000 | +8.7% | 511,806 | +9.9% | 0.01% | 0.0% |
| Q1 2017 | $6,037,000 | +29.9% | 465,766 | -1.0% | 0.01% | +20.0% |
| Q4 2016 | $4,649,000 | -11.1% | 470,492 | +8.7% | 0.01% | -16.7% |
| Q3 2016 | $5,227,000 | +62.1% | 432,651 | +15.8% | 0.01% | +50.0% |
| Q2 2016 | $3,225,000 | -22.8% | 373,642 | -15.3% | 0.00% | -20.0% |
| Q1 2016 | $4,176,000 | -47.1% | 440,935 | -3.2% | 0.01% | -54.5% |
| Q4 2015 | $7,897,000 | +37.6% | 455,630 | +6.7% | 0.01% | +37.5% |
| Q3 2015 | $5,738,000 | -31.0% | 427,195 | +16.0% | 0.01% | -27.3% |
| Q2 2015 | $8,318,000 | +87.0% | 368,375 | +18.3% | 0.01% | +83.3% |
| Q1 2015 | $4,447,000 | +55.4% | 311,355 | +5.0% | 0.01% | +50.0% |
| Q4 2014 | $2,861,000 | +9.7% | 296,421 | +3.5% | 0.00% | 0.0% |
| Q3 2014 | $2,607,000 | -5.9% | 286,427 | +2.2% | 0.00% | -20.0% |
| Q2 2014 | $2,769,000 | -19.6% | 280,183 | +3.4% | 0.01% | -16.7% |
| Q1 2014 | $3,443,000 | -7.1% | 271,047 | +9.7% | 0.01% | -14.3% |
| Q4 2013 | $3,706,000 | +47.1% | 247,174 | +8.3% | 0.01% | +40.0% |
| Q3 2013 | $2,520,000 | +58.7% | 228,260 | +10.5% | 0.01% | +25.0% |
| Q2 2013 | $1,588,000 | – | 206,483 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |